chevron_left
Companies to Watch: Next Generation Gene Editing
What’s next for the field of gene editing
Startups, targets and indications driving the next generation of gene editing therapeutics
The FDA’s late-2023 approval of Casgevy™ and Lyfgenia™ for the treatment of sickle cell disease and beta thalassemia was a watershed event ushering in the age of gene editing therapeutics. What’s next for this burgeoning field of medical science?
Companies to Watch: Gene Editing will explore:
- As-yet under-the-radar startups, and the targets and indications they are probing
- Clinical, regulatory, market access and IP challenges that would-be entrants to the space must navigate
- The potential impact of these therapeutics on regulators, payers, clinicians and patients